论文部分内容阅读
目的：评价哌拉西林舒巴坦静脉注射治疗慢性阻塞性肺病患者重症肺部感染的临床疗效和安全性。方法：2010年6月～2011年6月我院住院确诊慢性阻塞性肺病（Chronic Obstructive Pulmonary Disease，COPD）的重症肺部感染老年患者60例随机分为哌拉西林舒巴坦治疗组（n=30例）和头孢匹胺对照组（n=30例）。治疗组用0.9%生理盐水100ml+哌拉西林舒巴坦2.5 g，静脉滴注，每天2次；对照组用0.9%生理盐水100ml+头孢匹胺2.0 g，静脉滴注，每天2次，疗程7～14天。结果：治疗前后对患者的体温、症状、体征、胸片、白细胞计数检查、细菌学检查结果对比，治疗组与对照组有效率分别为90%和56.6%。哌拉西林舒巴坦组明显高于头孢匹胺组，有效率差异有统计学意义（P<0.05）。结论：哌拉西林舒巴坦对治疗慢性阻塞性肺病患者重症肺部感染临床疗效好，是一种抗菌谱广、细菌耐药率低、杀菌能力强且安全的抗菌药物。“,” Objective: To evaluate the curative effect and safety of intravenous injection piperacil in and sulbactam in treating chronic obstructive pulmonary disease(COPD) patients with severe pulmonary infection.Methods: 60 patients with COPD from June 2010 to June 2011 were randomly divided treatment group(n=30, using Pipemeil in and Sulbactam),and control group(n=30,using Cefpiramide).Patients in the treatment group were injected with physiological saline(100 m1)and piperacil in/suibactam (2.5g), twice every day.Meanwhile, the patients in the control group were injected with ceftazidime (2.0g),physiological saline(100 m1),once in 12 hours.The period of treatment was 7—14 days.Results: Before and after treatment, comparing with the patients’ temperature, symptoms, signs, chest, white blood cel count check, bacteriological examination results, the curative efficiency for the treatment group and the control group were 90% and 56.6% respectively.It showed that the curative efficiency of treatment group was obviously higher than the control group.This is obviously difference of curative efficiency was significant in statistics (P<0.05).There was no distinctive different in respect of side effect.Conclusion: Piperacil in and sulbactam is a high efficiency antibiotic with low side effect in curing chronic obstructive pulmonary disease patients with severe pulmonary infection.